Veeva：2023年交易后：并购后技术整合的成功因素白皮书（英文版）

Deal activity in life sciences might be down but it'scertainly not out. The sector's M&A volumes seemed topeak at $414 billion in 2019 after a series of landmarkdeals, including BMS acquiring Celgene (worth $74billion) and AbbVie purchasing Allergan ($63 billion).While the same pattern of mega-deals has not playedout in 2023, biopharma companies of all shapes andsizes continue to seek tie-ups to improve operatingmargins and expand R&D pipelines [Figure 1l, includingPfizer's $43 billi